唑来膦酸预防肿瘤骨转移的研究进展

摘要

Skeletal - related events(SRES)of bone metastaseslimitpatientsˊfunctional independence and undermine their qualityof life. Zoledronic acid(ZOL),the third generation of Bisphosphonates(BPs),is integral in the treatment regimen of patients with bone metastasis and has demonstratedefficacy in delaying the onset and reducing the inci-dence of SREs. Data from preclinical andclinical studies suggest that ZOL may have a great potential for the prevention of bone metastasis. The mechanisms may includeinduction ofapoptosis,inhibition of tumour cell invasion and angiogene-sis,and cell -cycle arrest.Therefore,patients with early -stage diseasemay benefit from early ZOL therapybefore bone metastasis develops. The present reviewassesses theavailable preclinical and clinical evidence ofthe prevent effect of ZOL in bone metastasis.%骨转移导致的骨相关事件使患者生存时间缩短，生活质量下降，同时也增加了患者家庭的经济负担。研究表明，第三代双膦酸盐（Bisphosphonate，BPs）唑来膦酸（Zoledronic acid，ZOL）在治疗多种实体瘤骨转移骨相关事件以及延缓骨相关事件的发生方面有效。目前大量临床前及临床研究提示：ZOL 可能具有预防骨转移的作用。其机制可能涉及阻滞肿瘤细胞周期、诱导肿瘤细胞凋亡、抑制肿瘤细胞侵袭和肿瘤血管生成。因此，ZOL 可能对没有发生骨转移的早期癌症患者有预防骨转移的作用。本文就唑来膦酸预防骨转移的最新研究进展做一综述。